Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential

Area of Science:

• Pulmonology
• Genetics
• Pharmacology

Background:

• Alpha-1 antitrypsin deficiency (AATD) is a rare autosomal genetic disorder.
• It significantly increases susceptibility to pulmonary emphysema and liver disease.
• Despite being recognized for years, AATD remains underdiagnosed, hindering effective treatment.

Purpose of the Study:

• To review the disease process, diagnosis, and treatment of AATD.
• To evaluate the efficacy of AAT augmentation therapy in managing AATD.
• To assess the impact of augmentation therapy on disease progression and patient outcomes.

Main Methods:

• Review of existing literature on AATD.
• Analysis of AAT augmentation therapy mechanisms and effects.
• Assessment of clinical outcomes associated with augmentation therapy.

Main Results:

• AAT augmentation therapy increases serum and lung AAT levels.
• Therapy restores anti-elastase capacity and reduces lung inflammation.
• Augmentation therapy slows lung density loss, improving outcomes like lung function decline and mortality.

Conclusions:

• AAT augmentation therapy is the primary pharmacological treatment for AATD.
• Wider testing, including primary care, could lead to earlier diagnosis and treatment.
• Earlier intervention can improve outcomes for individuals with AATD-induced lung disease.